Full-Time

Corporate Controller

Pleasanton, CA

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$250k - $270k/yr

+ Stock options + Variable incentive plan

Pleasanton, CA, USA

Hybrid

Hybrid schedule—minimum 3 days/week on-site at Pleasanton headquarters.

Category
Accounting (1)
Requirements
  • 10-15+ years of high-growth accounting experience, with at least 5 years demonstrated experience in a controllership role
  • experience building and scaling accounting functions at fast growing medical device companies or other FDA regulated environments
  • controllership experience in a public company subject to SOX 404A is preferred
  • strong expertise in Accounting systems and internal controls with advanced proficiency in US GAAP and audit best practices
  • expertise in building internal controls structures compliant with SOX 404A and the COSO Internal Control—Integrated Framework
  • ability to deliver high quality quarterly financial statements, audit packages and 10K/Q reporting each quarter
  • excellent communication and partnership skills with stakeholders; ability to engage with executives
  • growth mindset and comfort with ambiguity; ability to build systems and processes in a dynamic environment
  • must be able to sit for up to 8 hours/day
  • work location in Pleasanton with hybrid schedule minimum 3 days per week in headquarters
  • travel approximately 5%
  • Bachelor’s degree in Accounting, Finance, or related field; CPA or Masters in Accounting strongly preferred
  • experience with regulated environments including FDA regulations and HCP Sunshine Act reporting strongly preferred
  • experience in an S-1 registration process is a plus
  • significant experience in U.S. taxes including Federal and multistate income taxes, sales taxes and property taxes
  • ability to manage sensitive information with discretion and ensure alignment with corporate and regulatory standards
Responsibilities
  • Lead Calyxo’s Accounting Function: Manage a team of seven to provide full accounting support to the organization, including managing day-to-day activities, timely and accurate preparation of monthly, quarterly and annual financial statements in accordance with US GAAP, completion of external audits, and payroll and tax reporting
  • Drive efficient monthly accounting closes: Complete monthly, quarterly and annual accounting closes, financial statement preparation, audit preparation and internal controls testing within timelines that would support SEC public reporting, including reviews of journal entries and account reconciliations
  • Own Revenue Recognition: Partner with Finance to timely track sales including rebates and GPO fees and ensure revenue is properly recognized per US GAAP
  • Manage cost accounting: Deeply understand cost drivers in our products and drive sustained margin improvement and comprehensive cost reporting; strong knowledge of cost accounting and experience supporting both internal and contract manufacturing environments
  • Treasury and Risk Management: Work with VP Accounting on short-term investments to manage yield and preservation of capital and annual insurance renewals; ensure compliance with debt and equity quarterly information requirements
  • Tax: Ensures compliance with local, state, and Federal statutory tax requirements; timely providing outside tax preparers with accounting information for income tax provisions and tax returns and managing sales tax reporting using Avalara
  • Regulatory Compliance: Manage accounting areas including expense reports to ensure compliance with regulatory reporting requirements such as the Physician Payments Sunshine Act
  • Processes and Systems: Drive exponential improvements in systems and processes to keep pace with the growth of the company and work cross-functionally to implement them
  • Internal Controls: Protects assets and ensure effective financial reporting by establishing, monitoring, and enforcing internal controls
  • People: Drive the accounting team’s job results by coaching, counseling, planning, monitoring, and appraising job results. Crosstrain and continuously develop team to increase flexibility and capacity
  • Equity Reporting: Maintain quarterly stock option processing, stock compensation expense accounting and equity reporting within Carta or other equity software
  • Performs other related duties as assigned by Manager
Desired Qualifications
  • Experience building and scaling accounting functions in fast growing medical device companies or FDA regulated environments (preferred)
  • Controllership experience in a public company subject to SOX 404A preferred
  • CPA or Masters in Accounting strongly preferred
  • Experience with regulated environments including FDA regulations and HCP Sunshine Act reporting strongly preferred
  • S-1 registration process experience is a plus
  • Knowledge of NetSuite, Salesforce, Avalara, Concur, Carta and others (technically not a 'desirable' but listed as additional requirements)

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.